临床参数在预测膀胱癌结局方面优于分子亚型:来自多个队列(包括TCGA)的结果
研究评估简化分子分型方法与已建立分类能否预测肌层浸润性膀胱癌结局,纳入机构队列52例(含肌层浸润性39例)、Oncomine数据集151例和TCGA数据集402例。结果显示MCG-1与MCG-Ext亚型在单变量和Kaplan-Meier分析中未预测结局,多变量分析中N分期、T分期、M分期和/或患者年龄预测转移、癌特异性生存和总生存,临床参数在多个队列和分型分类中优于亚型预测结局。
要点
- MCG-1亚型在单变量或Kaplan-Meier分析中未预测结局。
- 多变量分析中N分期、T分期、M分期和/或年龄预测转移与生存。
- 在多个队列和分型分类中,临床参数预测结局优于分子亚型。
核心结论
- 分子亚型反映膀胱肿瘤异质性并与肿瘤分级相关,但在多个队列和分型分类中临床参数预测结局优于亚型。
研究设计与样本
- 研究纳入机构队列1的52例患者(含39例肌层浸润性膀胱癌)、Oncomine数据集151例肌层浸润性膀胱癌和TCGA数据集402例肌层浸润性膀胱癌。
- 使用仅包含已发表研究中常见转录本的简化面板(MCG-1和MCG-Ext)进行分型,分析预测转移、癌特异性生存、总生存和无复发生存。
- TCGA数据集进一步使用Lund分类法、膀胱癌分子分类共识组和TCGA 2017 mRNA亚型分类进行分析。
主要发现
- 队列1和Oncomine数据集的肌层浸润性膀胱癌标本显示转录本和蛋白表达存在瘤内异质性。
- MCG-1亚型在单变量或Kaplan-Meier分析中未预测结局。
- 多变量分析中N分期(p≤0.007)、T分期(p≤0.04)、M分期(p=0.007)和/或患者年龄(p=0.01)预测转移、癌特异性生存和总生存,和/或顺铂为基础辅助化疗反应。
- TCGA数据集中MCG-1和MCG-Ext亚型在单变量和Kaplan-Meier分析中与总生存相关但不与无复发生存相关;TCGA数据集402例中包括21例低级别标本,亚型与肿瘤分级相关(p=0.005),但肌层浸润性膀胱癌中小于1%为低级别,仅在高级别标本中MCG-1和MCG-Ext亚型不能预测总生存。
- 单变量分析中膀胱癌分子分类共识组、TCGA 2017和Lund分类法的亚型与肿瘤分级(p<0.0001)和总生存(p=0.01至<0.0001)相关;无论何种分类,亚型预测总生存和无复发生存的敏感性和特异性约为50%至60%;多变量分析中N分期和淋巴血管侵犯持续预测无复发生存和总生存(p分别为0.039和0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Studies indicate that molecular subtypes in muscle invasive bladder cancer predict the clinical outcome. We evaluated whether subtyping by a simplified method and established classifications could predict the clinical outcome. MATERIALS AND METHODS: We subtyped institutional cohort 1 of 52 patients, including 39 with muscle invasive bladder cancer, an Oncomine™ data set of 151 with muscle invasive bladder cancer and TCGA (The Cancer Genome Atlas) data set of 402 with muscle invasive bladder cancer. Subtyping was done using simplified panels (MCG-1 and MCG-Ext) which included only transcripts common in published studies and were analyzed for predicting metastasis, and cancer specific, overall and recurrence-free survival. TCGA data set was further analyzed using the Lund taxonomy, the Bladder Cancer Molecular Taxonomy Group Consensus and TCGA 2017 mRNA subtype classifications. RESULTS: Muscle invasive bladder cancer specimens from cohort 1 and the Oncomine data set showed intratumor heterogeneity for transcript and protein expression. MCG-1 subtypes did not predict the outcome on univariate or Kaplan-Meier analysis. On multivariate analysis N stage (p ≤0.007), T stage (p ≤0.04), M stage (p=0.007) and/or patient age (p=0.01) predicted metastasis, cancer specific and overall survival, and/or the cisplatin based adjuvant chemotherapy response. In TCGA data set publications showed that subtypes risk stratified patients for overall survival. Consistently the MCG-1 and MCG-Ext subtypes were associated with overall but not recurrence-free survival on univariate and Kaplan-Meier analyses. TCGA data set included 21 low grade specimens of the total of 402 and subtypes associated with tumor grade (p=0.005). However, less than 1% of muscle invasive bladder cancer cases are low grade. In only high grade specimens the MCG-1 and MCG-Ext subtypes could not predict overall survival. On univariate analysis subtypes according to the Bladder Cancer Molecular Taxonomy Group Consensus, TCGA 2017 and the Lund taxonomy were associated with tumor grade (p <0.0001) and overall survival (p=0.01 to <0.0001). Regardless of classification, subtypes had about 50% to 60% sensitivity and specificity to predict overall and recurrence-free survival. On multivariate analyses N stage and lymphovascular invasion consistently predicted recurrence-free and overall survival (p=0.039 and 0.003, respectively). CONCLUSIONS: Molecular subtypes reflect bladder tumor heterogeneity and are associated with tumor grade. In multiple cohorts and subtyping classifications the clinical parameters outperformed subtypes for predicting the outcome.
引用
- Morera DS, Hasanali SL, Belew D, et al. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. J Urol. 2019. PMID: 31112107. doi:10.1097/JU.0000000000000351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。